Apolipoprotein A1 is associated with pulmonary vascular resistance and adverse clinical outcomes in patients with pulmonary hypertension secondary to heart failure
Open Access
- 1 July 2022
- journal article
- research article
- Published by Wiley in Pulmonary Circulation
- Vol. 12 (3) , e12096
Abstract
Pulmonary hypertension secondary to heart failure (HF‐PH) combined with pulmonary vascular remodeling has a high mortality rate. Apolipoprotein A1 (ApoA1) has been shown to adversely affect outcomes in patients with HF. A prospective follow‐up study was performed on 239 consecutive patients with HF‐PH who underwent right heart catheterization. Proteomics technology was used to analyze different proteins in plasma between post‐ and precapillary pulmonary hypertension (CpcPH) and isolated postcapillary pulmonary hypertension (IpcPH) filtered by propensity score matching. Ultimately, 175 patients were enrolled and followed for an average of 4.4 years. Lipoprotein components in plasma were measured, and the following clinical events were tracked. Proteomics data showed that lipid metabolism and inflammation were different between CpcPH and IpcPH. ApoA1 levels in HF‐PH patients with CpcPH were lower than those in HF‐PH patients with IpcPH. The patients with lower ApoA1 levels (≤1.025 g/L) were in a higher New York Heart Association class and had high levels of NT‐proBNP, mean pulmonary artery pressure, PVR, and diastolic pressure gradient. Besides, HF‐PH patients with lower ApoA1 levels had a 2.836‐fold higher relative risk of comorbid CpcPH compared with patients with higher ApoA1 levels. Moreover, patients with lower ApoA1 levels had a lower survival rate after adjusting for CpcPH. In conclusion, ApoA1 levels were negatively correlated with PVR levels. Lower ApoA1 levels were an independent risk factor for pulmonary vascular remodeling in HF‐PH patients. The survival of HF‐PH patients with lower ApoA1 levels was reduced.Keywords
This publication has 26 references indexed in Scilit:
- Long-Term Survival and Apolipoprotein A1 Level in Chronic Heart Failure: Interaction With Tumor Necrosis Factor α −308 G/A PolymorphismJournal of Cardiac Failure, 2017
- Emerging Roles of Apolipoprotein E and Apolipoprotein A-I in the Pathogenesis and Treatment of Lung DiseaseAmerican Journal of Respiratory Cell and Molecular Biology, 2016
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureEuropean Heart Journal, 2016
- Apolipoprotein A-I Mimetic Peptide 4F Rescues Pulmonary Hypertension by Inducing MicroRNA-193-3pCirculation, 2014
- A Novel Paradigm for Heart Failure With Preserved Ejection FractionJACC, 2013
- The Macrophage Cholesterol Exporter ABCA1 Functions as an Anti-inflammatory ReceptorJournal of Biological Chemistry, 2009
- Lipoprotein Components and Risk of Congestive Heart Failure in 84 740 Men and Women in the Apolipoprotein MOrtality RISk Study (AMORIS)European Journal of Heart Failure, 2009
- Predictors of Fatal and Non-Fatal Outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): Incremental Value of Apolipoprotein A-1, High-Sensitivity C-Reactive Peptide and N-terminal pro B-type Natriuretic PeptideEuropean Journal of Heart Failure, 2009
- The Cholesterol Paradox in Heart FailureCongestive Heart Failure, 2007
- Association of Low Serum Levels of Apolipoprotein A-I With Adverse Outcomes in Patients With Nonischemic Heart FailureJournal of Cardiac Failure, 2007